Modality
Small Molecule
MOA
PRMT5i
Target
TYK2
Pathway
T-cell
T2DAS
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Mar 2029
Phase 1Current
NCT07284752
574 pts·T2D
2022-02→2029-03·Terminated
NCT08326653
2,579 pts·AS
2018-07→2026-01·Terminated
3,153 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-222mo agoPh2 Data· AS
2029-03-042.9y awayPh2 Data· T2D
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2026-01-22 · 2mo ago
AS
Ph2 Data
2029-03-04 · 2.9y away
T2D
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07284752 | Phase 1/2 | T2D | Terminated | 574 | ORR |
| NCT08326653 | Phase 1/2 | AS | Terminated | 2579 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C |